New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 5, 2014
09:01 EDTEXASFDA confirms date for Exact Sciences' advisory committee
Exact Sciences announced that the U.S. Food and Drug Administration has confirmed by notice in the Federal Register that its Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee will review the premarket approval application for the company’s Cologuard stool-DNA-based, non-invasive colorectal cancer screening test on March 27.
News For EXAS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 26, 2015
15:49 EDTEXASExact Sciences says CMS advisors vote to maintain Cologuard reimbursement rate
Subscribe for More Information
August 24, 2015
08:00 EDTEXASExact Sciences price target lowered to $26 from $32 at Canaccord
Canaccord lowered its price target on Exact Sciences to $26 from $32 to reflect dilution of the large secondary offering. The firm maintains its Buy rating on Exact Sciences shares, citing its sales force expansion, payer traction and a high probability of a positive outcome from the USPSTF decision.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use